Tasly Pharmaceutical Group Co., Ltd
600535
Κατάταξη σε μετοχές
#4771
Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in... Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in Tianjin, China, is actively engaged in the biological medicine, health, and medical service industries within China. Its extensive product catalog encompasses a wide range of goods, including both traditional herbal and modern chemical medicines, alongside various health supplements. The firm also supplies key pharmaceutical ingredients (APIs), concentrated herbal granules, herbal extracts, and a diverse selection of tea products. Beyond its core pharmaceutical offerings, Tasly manufactures cosmetic lines featuring items such as moisturizing lotions, facial creams, eye creams, and cleansing foams. Additionally, its consumer goods division provides daily hygiene essentials like sanitary and carefree pads, in addition to specialized soaps made with honey-propolis and pollen. The company further distributes medical equipment, including different types of massage devices like tappers and cushions, as well as circulation-enhancing machines. Tasly's market presence extends globally, with significant exports directed to the United States, Russia, and numerous countries across Europe, Africa, and other parts of Asia.
Τιμή μετοχής
$2.05
Κεφαλαιοποίηση
$3.07B
Αλλαγή (1 ημέρα)
-1.37%
Αλλαγή (1 έτος)
-7.80%
Χώρα
CN
Εμπόριο Tasly Pharmaceutical Group Co., Ltd (600535)
Κατηγορία
Healthcare
Κέρδη για την Tasly Pharmaceutical Group Co., Ltd (600535)
Κέρδη τον 2026 TTM: 0
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Tasly Pharmaceutical Group Co., Ltd, τα τρέχοντα κέρδη της εταιρείας είναι 0. Το 2026, η εταιρεία παρουσίασε κέρδη 0, ίσο με των κερδών του 2026 που ήταν 0. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Tasly Pharmaceutical Group Co., Ltd από 2001 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2025 | $192.27M | 31.32% |
| 2024 | $146.41M | -15.13% |
| 2023 | $172.51M | -809.84% |
| 2022 | $-24.30M | -105.67% |
| 2021 | $428.51M | 92.12% |
| 2020 | $223.04M | 16.70% |
| 2019 | $191.12M | -32.79% |
| 2018 | $284.34M | 6.54% |
| 2017 | $266.90M | 23.84% |
| 2016 | $215.52M | -22.05% |
| 2015 | $276.48M | -1.18% |
| 2014 | $279.80M | 19.89% |
| 2013 | $233.39M | 34.76% |
| 2012 | $173.19M | 38.94% |
| 2011 | $124.65M | 48.07% |
| 2010 | $84.18M | 44.00% |
| 2009 | $58.46M | 26.80% |
| 2008 | $46.10M | 49.47% |
| 2007 | $30.84M | -8.16% |
| 2006 | $33.58M | 16.86% |
| 2005 | $28.74M | 10.44% |
| 2004 | $26.02M | 22.03% |
| 2003 | $21.32M | 21.82% |
| 2002 | $17.50M | 12.42% |
| 2001 | $15.57M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
